Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche Will Acquire Two Technology Firms

July 28, 2008 | A version of this story appeared in Volume 86, Issue 30

Roche has agreed to shell out more than $300 million for two companies that will broaden its technology platform. The $125 million purchase of Madison, Wis.-based Mirus Bio adds RNAi delivery technology, which will help advance Roche's efforts to develop gene-silencing therapeutics. Last year, Roche forged a deal to license Alnylam's technology for developing RNAi-based drugs. In a separate move, Roche agreed to pay $190 million for Arius Research, a Canadian firm with technology to quickly identify antibodies on the basis of their ability to modulate disease. The Swiss drug firm says the Arius platform will help determine cancer and immunology drug candidates.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.